References
- 1. Todd J, Fishaut M, Kapral F. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;2(8100):1116-8.
- 2. David M, Daum R. Community-Associated Methicillin Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic. Clin Microbiol Rev. 2010;23:616-87.
- 3. DeVries AS, Lesher L, Schlievert PM, et al. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS One. 2011;6:e22997.
- 4. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:147-59.
- 5. Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby- Teglund A. Clinical Efficacy of Polyspecific Intravenous Immunoglobulin Therapy in Patients With Streptococcal Toxic Shock Syndrome: A Comparative Observational Study. Clin Infect Dis. 2014;59:851-7.
- 6. Brosnahan AJ, Schlievert PM. Gram-positive bacterial superantigen outside-in signaling causes toxic shock syndrome. FEBS J. 2011;278:4649-67.
- 7. Herzer CM. Toxic shock syndrome: Broadening the differential diagnosis. J Am Board Fam Pract. 2001;14:131-6.
- 8. Marton M. Staphylococcal Toxic Shock Syndrome Caused By An Intravaginal Product. A Case Report. J Crit Care Med. 2016;2:51-5.